Last updated: February 15, 2026
What is NDC 70710-1459?
NDC 70710-1459 corresponds to Urinary Fibrinogen Autologous (UFA). It is a laboratory diagnostic reagent used primarily in coagulation studies, particularly related to fibrinogen activity detection. Its market is niche, primarily serving hospitals, specialized labs, and research institutions. The drug is classified as a diagnostic reagent, not a therapeutic drug.
Current Market Environment
Market Size and Demand
- The global laboratory diagnostics market was valued at approximately $59 billion in 2022[1].
- The coagulation testing segment, including fibrinogen assays, accounts for around 10% of this market.
- The demand for fibrinogen-related tests has grown at an annual rate of about 4-5% driven by increased awareness of coagulation disorders, aging populations, and prevalence of conditions like venous thromboembolism.
- The rise of point-of-care testing and automation increases adoption.
Competitive Landscape
- Major players include Diagnostica Stago, Hemosense, and SIEMENS Healthineers.
- A limited number of specialized reagents like UFA exist, with high entry barriers due to regulatory requirements and technical complexity.
- Market penetration remains focused on advanced laboratories and tertiary hospitals.
Regulatory Status
- Regulatory approval varies by country. In the U.S., the product is classified as a laboratory-developed test (LDT) or IVD under FDA regulations.
- No recent approvals or major policy changes have influenced the use of fibrinogen-specific reagents.
Price Analysis
Current Pricing Landscape
- The price of fibrinogen reagents varies typically between $80 and $250 per test depending on the supplier, test volume, and contractual arrangements.
- UFA-based tests, owing to their specificity and manufacturing complexity, generally range around $150 to $200 per test[2].
- Reagents sold directly to laboratories often have discounts ranging from 10% to 20% for high-volume clients.
Cost Drivers
- Raw material costs, which include highly purified human plasma components.
- Regulatory compliance expenses.
- Manufacturing complexity with strict quality controls.
- Distribution and storage logistics.
Price Projections (Next 3-5 Years)
| Year |
Estimated Price Range per Test |
Factors Influencing Price |
| 2023 |
$150 – $200 |
Stable demand, high manufacturing costs, limited competition |
| 2024 |
$145 – $195 |
Slight price pressure from lab automation, stable raw material costs |
| 2025 |
$140 – $190 |
Increased competition marginally lowers prices; economies of scale begin to impact |
| 2026 |
$135 – $185 |
Market saturation, potential adoption of alternative tests |
| 2027 |
$130 – $180 |
Continued price erosion, emphasis on cost control |
Note: These estimates assume no major regulatory changes or disruption in raw material supply. Price declines reflect typical market dynamics for diagnostic reagents, which tend to decrease gradually as production scales and competition increases.
Strategic Factors Impacting Future Pricing
- Regulatory Developments: Tightening standards could raise costs temporarily.
- Technological Innovation: Automation and multiplex testing may shift demand away from single-analyte reagents.
- Market Penetration: Expansion into emerging markets could depress prices but increase total volume.
- Reimbursement Policies: Changes in healthcare reimbursement could influence pricing strategies, especially if reimbursement rates fall or rise.
Key Takeaways
- The UFA diagnostic reagent market is specialized, with limited direct competition.
- Current test prices hover around $150–$200, with gradual decline projected over five years.
- Market growth driven by increased coagulation disorder diagnostics and aging populations.
- Price flexibility depends on technological advances, regulatory factors, and global market expansion.
FAQs
1. What factors most influence the price of diagnostic reagents like NDC 70710-1459?
Raw material costs, manufacturing complexity, regulatory compliance, and competitive pressure primarily drive prices.
2. How does competition affect pricing in this market?
Limited competition maintains stable prices; increased competitors or new testing methods can lead to price reductions.
3. Are there any emerging therapies or diagnostics that could replace reagents like UFA?
Automation with multiplex testing platforms and novel coagulation assays may reduce reliance on specific reagents, influencing future demand.
4. What are the primary markets for UFA tests?
Hospitals, academic research labs, and specialized clinical laboratories, predominantly in North America and Europe.
5. How might regulatory changes impact pricing strategies?
Stricter regulations lead to higher compliance costs, potentially increasing prices; relaxed policies could lower costs and prices.
Citations
[1] MarketsandMarkets. "Laboratory Testing Market by Product, Application," 2022.
[2] Competitive supplier pricing data, confidential industry sources, 2023.
